skip navigation links
National Cancer Institute
EVS Logo NCI Term Browser Enterprise Vocabulary Services
Terminologies Value Sets Mappings
Version: 17.10e (Release date: 2017-10-30)
SearchBox Top
SearchBox Bottom
Zirconium Zr 89 Bevacizumab (Code C82656)

Terms & Properties Synonym Details Relationships Mapping View All  
Terms & Properties

Preferred Name: Zirconium Zr 89 Bevacizumab

Definition: A radioimmunoconjugate comprised of the recombinant humanized monoclonal antibody bevacizumab labeled with the radioisotope zirconium Zr 89 (Zr 89) with radioisotopic activity and potential imaging use. The antibody moiety of zirconium Zr 89 bevacizumab targets and binds to the extracellular domain of the vascular endothelial growth factor receptor (VEGFR). Upon binding, the radioisotope moiety may be detected using positron emission tomography (PET), allowing the imaging and quantification of VEGFR-expressing tumor cells. VEGFR, a tyrosine kinase, is overexpressed on the cell surfaces of various tumor cell types.

Label: Zirconium Zr 89 Bevacizumab

NCI Thesaurus Code: C82656 (Search for linked caDSR metadata)  (search value sets)

NCI Metathesaurus Link: C2826356  (see NCI Metathesaurus info)

Synonyms & Abbreviations: (see Synonym Details)
Zirconium Zr 89 Bevacizumab

External Source Codes: 
PDQ Closed Trial Search ID 636152
PDQ Open Trial Search ID 636152 (check for NCI PDQ open clinical trial info)
UMLS CUI C2826356

Other Properties:
     Name Value (qualifiers indented underneath)
code C82656
Legacy_Concept_Name Zirconium_Zr_89_Bevacizumab
Semantic_Type Amino Acid, Peptide, or Protein
Semantic_Type Indicator, Reagent, or Diagnostic Aid

Additional Concept Data: 
Defined Fully by Roles: No  


Mainbox Bottom